Disease tropism of c-erbB

Effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation

R. J. Pelley, N. J. Maihle, C. Boerkoel, H. K. Shu, T. H. Carter, C. Moscovici, Hsing-Jien Kung

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Avian leukosis virus induces erythroleukemia in chickens by proviral insertional mutation of the proto-oncogene c-erbB. The product of the insertionally activated c-erbB locus lacks the extracellular ligand-binding domain and is strictly leukemogenic. It has previously been demonstrated that the disease spectrum associated with aberrant c-erbB expression can be expanded by structural perturbation of the cytoplasmic domain of this protein. In this report, we use mutagenesis and retroviral vectors to identify specific mutations in the carboxyl-terminal domain of the insertionally activated c-erbB product that are sufficient to activate the sarcomagenic potential of this protein. Interestingly, a point mutation in the kinase domain appears to be sufficient for sarcomagenic activation. However, removal of the terminal tyrosine residue of the c-erbB product, implicated in modulating kinase activity, does not lead to a fully transforming phenotype. These studies suggest that there are multiple ways to activate the fibroblast-transforming potential of the insertionally activated c-erbB product. The conformation of this protein may play a more significant role in oncogenic activation than the phosphorylation status of the putative carboxyl-terminal autophosphorylation site.

Original languageEnglish (US)
Pages (from-to)7164-7168
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume86
Issue number18
StatePublished - 1989
Externally publishedYes

Fingerprint

Tropism
Tyrosine
Phosphotransferases
Avian Leukosis Virus
Leukemia, Erythroblastic, Acute
Protein Conformation
Mutation
Proto-Oncogenes
Point Mutation
Mutagenesis
Chickens
Fibroblasts
Phosphorylation
Ligands
Phenotype
Proteins
Protein Domains

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Disease tropism of c-erbB : Effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation. / Pelley, R. J.; Maihle, N. J.; Boerkoel, C.; Shu, H. K.; Carter, T. H.; Moscovici, C.; Kung, Hsing-Jien.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, No. 18, 1989, p. 7164-7168.

Research output: Contribution to journalArticle

@article{b99bdf867b34493991a971e43bb91d45,
title = "Disease tropism of c-erbB: Effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation",
abstract = "Avian leukosis virus induces erythroleukemia in chickens by proviral insertional mutation of the proto-oncogene c-erbB. The product of the insertionally activated c-erbB locus lacks the extracellular ligand-binding domain and is strictly leukemogenic. It has previously been demonstrated that the disease spectrum associated with aberrant c-erbB expression can be expanded by structural perturbation of the cytoplasmic domain of this protein. In this report, we use mutagenesis and retroviral vectors to identify specific mutations in the carboxyl-terminal domain of the insertionally activated c-erbB product that are sufficient to activate the sarcomagenic potential of this protein. Interestingly, a point mutation in the kinase domain appears to be sufficient for sarcomagenic activation. However, removal of the terminal tyrosine residue of the c-erbB product, implicated in modulating kinase activity, does not lead to a fully transforming phenotype. These studies suggest that there are multiple ways to activate the fibroblast-transforming potential of the insertionally activated c-erbB product. The conformation of this protein may play a more significant role in oncogenic activation than the phosphorylation status of the putative carboxyl-terminal autophosphorylation site.",
author = "Pelley, {R. J.} and Maihle, {N. J.} and C. Boerkoel and Shu, {H. K.} and Carter, {T. H.} and C. Moscovici and Hsing-Jien Kung",
year = "1989",
language = "English (US)",
volume = "86",
pages = "7164--7168",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "18",

}

TY - JOUR

T1 - Disease tropism of c-erbB

T2 - Effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation

AU - Pelley, R. J.

AU - Maihle, N. J.

AU - Boerkoel, C.

AU - Shu, H. K.

AU - Carter, T. H.

AU - Moscovici, C.

AU - Kung, Hsing-Jien

PY - 1989

Y1 - 1989

N2 - Avian leukosis virus induces erythroleukemia in chickens by proviral insertional mutation of the proto-oncogene c-erbB. The product of the insertionally activated c-erbB locus lacks the extracellular ligand-binding domain and is strictly leukemogenic. It has previously been demonstrated that the disease spectrum associated with aberrant c-erbB expression can be expanded by structural perturbation of the cytoplasmic domain of this protein. In this report, we use mutagenesis and retroviral vectors to identify specific mutations in the carboxyl-terminal domain of the insertionally activated c-erbB product that are sufficient to activate the sarcomagenic potential of this protein. Interestingly, a point mutation in the kinase domain appears to be sufficient for sarcomagenic activation. However, removal of the terminal tyrosine residue of the c-erbB product, implicated in modulating kinase activity, does not lead to a fully transforming phenotype. These studies suggest that there are multiple ways to activate the fibroblast-transforming potential of the insertionally activated c-erbB product. The conformation of this protein may play a more significant role in oncogenic activation than the phosphorylation status of the putative carboxyl-terminal autophosphorylation site.

AB - Avian leukosis virus induces erythroleukemia in chickens by proviral insertional mutation of the proto-oncogene c-erbB. The product of the insertionally activated c-erbB locus lacks the extracellular ligand-binding domain and is strictly leukemogenic. It has previously been demonstrated that the disease spectrum associated with aberrant c-erbB expression can be expanded by structural perturbation of the cytoplasmic domain of this protein. In this report, we use mutagenesis and retroviral vectors to identify specific mutations in the carboxyl-terminal domain of the insertionally activated c-erbB product that are sufficient to activate the sarcomagenic potential of this protein. Interestingly, a point mutation in the kinase domain appears to be sufficient for sarcomagenic activation. However, removal of the terminal tyrosine residue of the c-erbB product, implicated in modulating kinase activity, does not lead to a fully transforming phenotype. These studies suggest that there are multiple ways to activate the fibroblast-transforming potential of the insertionally activated c-erbB product. The conformation of this protein may play a more significant role in oncogenic activation than the phosphorylation status of the putative carboxyl-terminal autophosphorylation site.

UR - http://www.scopus.com/inward/record.url?scp=0024417692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024417692&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 7164

EP - 7168

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 18

ER -